🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What an amazing turnout to the first IBD Pharmacist Track at AIBD. Shubha Bhat, PharmD and I are so grateful for the opportunity to have this session!! Thank you to AIBD for making this happens! #AIBD2024

1️⃣st ever pharmacy track at #AIBD2024 ✅ Thanks to Miguel Regueiro Corey Siegel Millie Long Stephen B. Hanauer, MD @IBDConference for recognizing #PharmD as part of #IBD care teams and for those who came out to provide support for #PharmD education! 🙏

The 7th Stelara biosimilar has been FDA approved! Ustekinumab-stba (Steqeyma; Celltrion) is expected to launch 02/2025! 🎉 #Biosimilar #IBD #GITwitter -45 mg/0.5 mL or 90 mg/1 mL prefilled syringe -130 mg/26 mL intravenous infusion pharmacytimes.com/view/ustekinum…

Join us on January 14th at 6pm CST to participate in a dynamic discussion between Marita Kametas , Angelina Collins, NP , #KimberlyOrleck & David Choi, PharmD about sequencing, management and access to IL-23 therapies.

Please join us for this important discussion!! We will be discussing how to successfully start and keep patients on therapy and how to transition from IV to SQ successfully! #GITwitter #IBD

Clinical pharmacists should ideally be part of a multidisciplinary team to improve holistic care of IBD patients 🌸 Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases:

🚨 Today is the day! Register here so you do not miss out on this incredible ChatAPP IBD Case Series by APPs for APPs! uchicago.zoom.us/meeting/regist… #IBD #APPs #ChatAPP UChicagoIBD UChicago Digestive Diseases

Omvoh is now FDA approved for Crohn's disease! ##GITWITTER #IBD investor.lilly.com/news-releases/…

We are excited to be planning our third IBD Pharmacist Virtual Symposium for June 07, 2025! We are hoping to introduce Innovation Presentations that showcases amazing innovations by IBD pharmacy teams across the country! #GI #IBD #GITwitter

Tremfya is FDA approved for Crohn's disease! This has both IV (200 mg) and subq (400 mg) induction loading dose options followed by subq maintenance dose (100 mg or 200 mg). #GITwitter #IBD jnj.com/media-center/p…

One of the biggest challenges we have been encountering for #IBD care are the increasing role of quantity limit PAs! Although we are getting medications approved they are requiring a separate PA for the dose. These are leading to significant delays in care! #GITwitter

We have observed significantly higher rates (almost 30%) of acne with upadacitinib (JAKne) than in clinic trials (~7-8%). We found younger age, upadacitinib dose and female gender being risk factors for development! Amelia Kellar David T. Rubin, MD @Klein_Jeremy

ACG Clinical Guideline: Management of Crohn's Disease in... : Official journal of the American College of Gastroenterology | ACG journals.lww.com/ajg/fulltext/2… Anita Afzali MD, MPH, MHCM, FACG, AGAF ACG

With ease of starting IL23 for IBD (good insurance coverage, bridge program). Should we stop trying to dose escalate Stelara? There are substantial delays with appeals process (months) and extra work needed to appeal! #GITwitter #IBD

Excited to have published our data on Skyrizi IV to subq transition (95%) at week 12! Barriers to transition 1) access/cost to therapy, 2) confusion of week 12 injection (pts thought it was 8 weeks after last IV loading dose) Marita Kametas David T. Rubin, MD #IBD #GITwitter accpjournals.onlinelibrary.wiley.com/doi/10.1002/ja…